BioPharmSignal logoBioPharmSignal

Biotech News

CORRECTING and REPLACING Scholar Rock Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

Scholar Rock (SRRK)Scholar RockEarnings

Apitegromab Biologics License Application (BLA) resubmission and U.S. launch, following FDA approval, are anticipated in 2026 for the treatment of children and adults with spinal muscular atrophy (SMA) FDA completed constructive meeting with Catalent Indiana, LLC (part of Novo Nordisk), with

Related news

SRRKScholar Rock2026-03-03 12:00 EST

Scholar Rock Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

SRRKScholar Rock2026-08-06 11:00 EST

Scholar Rock Reports Second Quarter 2026 Financial Results and Recent Business Highlights

View all latest news

Scholar Rock

Myostatin Biology Scholar Rock develops therapies that selectively modulate growth factors in their latent forms. Its lead work targets myostatin to improve muscle function while preserving related signaling pathways. Apitegromab Apitegromab is a selective inhibitor of latent myostatin under FDA review for children and adults with spinal...

Recent company news

SRRKScholar Rock2026-08-07 20:20 EST

Scholar Rock Announces FDA Review of Apitegromab Biologics License Application (BLA) for Spinal Muscular Atrophy (SMA) to Progress with Second Fill-Finish Facility; Approval Decision Anticipated by September 30, 2026 Action Date

SRRKScholar Rock2026-08-06 11:00 EST

Scholar Rock Reports Second Quarter 2026 Financial Results and Recent Business Highlights

SRRKScholar Rock2026-07-29 12:00 EST

Scholar Rock to Present at the Canaccord Genuity 46th Annual Growth Conference

SRRKScholar Rock2026-07-20 12:00 EST

Scholar Rock Provides Update on Timing of Committee for Medicinal Products for Human Use (CHMP) Opinion for Apitegromab Marketing Authorisation Application (MAA) for Spinal Muscular Atrophy (SMA)

SRRKScholar Rock2026-07-17 20:15 EST

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Stock data

Close
52.64 USD
Market cap
5.35B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States